A vitamin B12 test is a blood test that measures how much of this nutrient is circulating in your system, and it is useful but imperfect for dementia evaluation. According to NICE's 2024 guideline NG239, there is no single "gold standard" test for B12 deficiency, so the result functions as one piece of evidence rather than a definitive yes-or-no answer. For someone newly diagnosed with dementia, or a family member pushing for answers, that distinction matters. The test can flag a treatable contributor to cognitive symptoms, but a normal result does not rule deficiency out, and a low result does not automatically explain the dementia.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why Doctors Order This Test for Dementia
- How Accurate Is the Result?
- Why the Same Number Can Mean Different Things at Different Labs
- What the Cost Looks Like
- What to Do With a Low or Borderline Result
- Frequently Asked Questions
Why Doctors Order This Test for Dementia
The American Academy of Neurology's dementia practice parameter lists B12 deficiency screening as a standard part of working up a new dementia diagnosis, alongside checks for hypothyroidism and structural brain lesions, because it is one of the few potentially treatable contributing causes. The logic is straightforward: B12 supports nerve function, and a shortage can produce memory problems, confusion, and slowed thinking that overlap with dementia symptoms.
This is a screening step, not a diagnostic ceiling. A clinician orders it to catch a reversible or partly reversible factor early, not because B12 deficiency is expected to be the whole story in most dementia cases.
How Accurate Is the Result?
Total serum B12 has a well-documented sensitivity problem. A laboratory proficiency survey concluded that a normal B12 result is inconclusive and a low result is not specific for true tissue-level deficiency, which is why methylmalonic acid (MMA) is used as a confirmatory add-on test.
In practice, the serum B12 number can miss real deficiency and can also flag a low level in someone whose tissues are not actually deficient. NICE's guideline reinforces this from the other direction: it explicitly advises against ruling out B12 deficiency just because a red blood count is normal or macrocytosis is absent, since deficiency often occurs without anemia. A commonly used interpretive scale treats serum B12 at or below 200 pg/mL as low and 201–350 pg/mL as borderline, and recommends resolving that borderline zone with plasma homocysteine, MMA, and intrinsic-factor or parietal-cell antibody testing.
- A normal result does not fully exclude deficiency.
- A low result does not confirm tissue-level deficiency on its own.
- Borderline results (201–350 pg/mL) need a second test to interpret.
- Absence of anemia is not a reason to skip testing.
Why the Same Number Can Mean Different Things at Different Labs
The cutoff that separates "normal" from "low" is not uniform. Reference ranges are assay- and lab-specific, and a 2026 UK multi-lab study found substantial national inconsistency in total-B12 thresholds.
One widely used testing platform, the Beckman Coulter DxI, applies a manufacturer cutoff of 145 ng/L (107 pmol/L), which is not interchangeable with the generic figures NICE cites. This means the same blood sample could read as normal on one lab's assay and low on another's. When comparing results across visits or providers, check whether the lab or testing method changed, since that alone can shift the number without any real change in B12 status.
What the Cost Looks Like
A basic serum B12 test is inexpensive on its own. U.S. Medicare-era rates from 2012 priced B12 at about $21.59, folate at about $21.06, and homocysteine at about $24.16, and a separate Canadian commentary put serum B12 at roughly $20 against about $160 for combined MMA and homocysteine testing.
The gap in price is why MMA is not used as a routine first-line screen. NICE's own 2024 resource-impact analysis for NG239 sets a unit cost of £30.40 per MMA test and notes it is more expensive than either active or total B12 testing. Clinicians reserve it for borderline or ambiguous cases rather than ordering it alongside every initial B12 check.
What to Do With a Low or Borderline Result
A low or borderline B12 reading is a starting point, not a conclusion. The practical next step is to add methylmalonic acid and/or homocysteine testing, with intrinsic-factor antibody testing if pernicious anemia is suspected, before deciding deficiency is or isn't present.
Treating confirmed deficiency does not guarantee improvement in dementia symptoms. A cohort presented at the AAN 2012 annual meeting found no evidence that B12 replacement reversed, stabilized, or slowed progression in patients who also had Alzheimer's disease, which suggests that coexisting B12 deficiency often does not explain the dementia itself. Correcting the deficiency remains worthwhile for other health reasons, but it should be treated as a separate issue from the underlying dementia diagnosis, with cognition reassessed afterward rather than assumed to improve.
- Ask whether the lab used a locally validated cutoff or a generic one.
- If the result is borderline (201–350 pg/mL), request MMA or homocysteine follow-up.
- If deficiency is confirmed, expect treatment followed by reassessment of cognitive symptoms, not an assumption that memory loss will reverse.
- Keep track of which lab and assay produced each result for future comparison.
Frequently Asked Questions
Can a B12 deficiency cause dementia on its own?
It can produce cognitive symptoms that overlap with dementia, but when deficiency coexists with Alzheimer's disease, treating it has not been shown to reverse or slow the underlying progression, based on cohort data presented at the AAN 2012 meeting.
Should I ask for the MMA test upfront instead of waiting?
Most clinicians order serum B12 first because MMA costs roughly £30.40 per NICE's 2024 resource-impact analysis, more than B12 testing alone, and reserve it for borderline or inconclusive results.
Does a normal blood count mean B12 deficiency isn't a factor?
No. NICE's guideline specifically warns against using a normal red blood count or absent macrocytosis to rule out deficiency, since deficiency frequently occurs without anemia.
